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Abstract
In this paper, we propose using mobile nanosensors (MNSs) for early stage anomaly detection. For
concreteness, we focus on the detection of cancer cells located in a particular region of a blood vessel.
These cancer cells produce and emit special molecules, so-called biomarkers, which are symptomatic
for the presence of anomaly, into the cardiovascular system. Detection of cancer biomarkers with
conventional blood tests is difficult in the early stages of a cancer due to the very low concentration of
the biomarkers in the samples taken. However, close to the cancer cells, the concentration of the cancer
biomarkers is high. Hence, detection is possible if a sensor with the ability to detect these biomarkers
is placed in the vicinity of the cancer cells. Therefore, in this paper, we study the use of MNSs that
are injected at a suitable injection site and can move through the blood vessels of the cardiovascular
system, which potentially contain cancer cells. These MNSs can be activated by the biomarkers close
to the cancer cells, where the biomarker concentration is sufficiently high. Eventually, the MNSs are
collected by a fusion center (FC) where their activation levels are read and exploited to declare the
presence of anomaly. We analytically derive the biomarker concentration in cancerous blood vessels as
well as the probability mass function of the MNSs’ activation levels and validate the obtained results via
particle-based simulations. Then, we derive the optimal decision rule for the FC regarding the presence
of anomaly assuming that the entire network is known at the FC. Finally, for the FC, we propose a
simple sum detector that does not require knowledge of the network topology. Our simulations reveal that
while the LRT detector achieves a higher performance than the sum detector, both proposed detectors
significantly outperform a benchmark scheme that uses fixed nanosensors at the FC.
I. INTRODUCTION
Molecular communication (MC) is an emerging technology enabling communication among
nanomachines. Inspired by biological systems, synthetic diffusion-based MC systems have been
proposed as a potential solution for communication in nanonetworks where molecules play the
2role of information carriers [1]. Nanonetworks are envisioned to facilitate revolutionary applica-
tions in areas such as biological engineering, healthcare, and environmental monitoring [2]–[4].
One of the key challenges in health monitoring and disease diagnosis applications is the prob-
lem of anomaly detection, e.g., early cancer detection, which has received significant attention in
medicine and other related fields [5], [6]. Since early cancer detection can significantly decrease
cancer mortality, great efforts have been devoted to the investigation of new technologies for
detecting the symptoms of cancer at an early stage [5]–[9]. These symptoms are characteristics
that can indicate the presence of anomaly, and include cancer biomarkers [5]. Cancer biomarkers
cover a broad range of biochemical entities such as nucleic acids, proteins, sugars, small metabo-
lites, and cytogenetic and cytokinetic parameters as well as entire cancer cells found in body
fluids [6]. Among these biomarkers, proteins are of particular interest since they are primarily
found in blood and urine where they can be measured with current medical technologies, such
as clinical blood tests [7], [8]. It has been shown in [9]–[11] that abnormal behavior/expressions
of protein biomarkers can be associated with particular cancers. For example, α-fetoprotein,
carcinoma antigen 125, carcinoembryonic antigen, and prostate-specific antigen are common
biomarkers for liver, ovarian, colorectal, and prostate cancers, respectively [12].
Conventional blood tests may not be able to detect biomarkers secreted by cancer cells in
the early stages of a cancer due to the very low concentration of the biomarkers inside the
cardiovascular system (CS) [7], [8]. However, close to the cancer cells, the concentration of the
cancer biomarkers is high such that reliable detection is possible if a corresponding sensor passes
in the vicinity of the cancer cells. In this paper, we propose the use of engineered nanosensors
for this purpose. Such nanosensors play a key role in nanomedicine and can carry and deliver
imaging probes, therapeutic agents, and biological materials to target sites such as specific organs,
tissues, and even particular cells [6], [13], [14]. The ability of engineered nanosensors to fast
and intelligently release, move, observe, and read inside the CS motivates the investigation of
the use of mobile nanosensors (MNSs) for anomaly detection [15]. In particular, MNSs can
be released from an injection site, move through the CS, become activated at sites of high
biomarker concentration, and eventually be captured at a fusion center (FC) which then decides
on the presence of an anomaly. The time interval between release and capture of the MNSs at
the FC is called the observation window and is on the order of a few minutes due to the fast
flow velocities inside CS.
Anomaly detection has been extensively studied in different fields, including computer science,
3segmentation of biomedical signals, and fraud detection for credit cards, see e.g. [16] and [17].
However, in the context of MC, the amount of related prior work is limited. In [18], anomaly
detection in molecular nanonetworks is studied and a suboptimal decision rule is employed
to combine the observations at the FC. More recently, in [19], both optimal and near-optimal
decision rules are developed for networks where nanosensors employ either one or multiple types
of molecules to relay their gathered information to the FC. However, both [18] and [19] assume
that the nanosensors are fixed, i.e., they do not move inside the CS. In [20], an MC system
for tumor detection in blood vessels is proposed. In this work, the authors assume that specific
nanorobots are injected into the CS which are attracted by the tumor cells. After detection of
a tumor, these nanorobots remain close to the tumor site and release secondary nanomachines
inside the blood vessel to relay the nanorobots’ information to specific receivers. Finally, in [21],
a graph-based model for mobile MC systems with several bio-nanomachines is proposed, and
the concentration of the bio-nanomachines is numerically evaluated. It is shown that similar to
[20], the concentration of the considered bio-nanomachines is high in the vicinity of tumor cells.
We note that the cardiovascular network is highly complex and the propagation of the molecules
within this network is therefore very complicated. Hence, most prior works relied on extensive
simulations to analyze sensing systems for the CS [20], [21]. On the contrary, in this paper, by
developing a simplified yet meaningful model for the CS, we establish an analytical framework
for analyzing the proposed detection system which provides useful insights for system design. In
particular, we consider collaborative anomaly detection where multiple MNSs are released at an
injection site into the CS to individually detect biomarkers. The MNSs are transported through
the CS and can detect the presence of biomarkers, which triggers the activation of the MNSs.
Nanosensors with such detection capabilities have already been reported in the literature, see [13]
and references therein. The MNSs may ultimately reach an FC which decides on the presence
of an anomaly based on the activation levels of the observed MNSs. Relying on multiple MNSs
is motivated by the fact that, in general, healthy cells also release a small amount of the same
type of biomarkers into the CS as the cancer cells. This introduces noise to the sensing process
of the MNS, which may have a large impact in the early stages of a cancer and may lead to
unreliable decisions. Moreover, a given MNS may not pass both the cancer cell or the FC on
its path through the CS. Therefore, detection reliability can be improved by employing multiple
MNSs. The contributions of this paper can be summarized as follows.
• Although in general the CS has a highly complex structure, we propose a simplified
4yet meaningful model for the blood vessels of the CS facilitating first-order insights about
the propagation of biomarkers and MNSs through the CS. In particular, we model blood
vessels as two-dimensional (2-D) rectangles and simplify existing models for the release
rate of biomarkers for both healthy and cancerous cells. We note that, in the presence of
cancer cells, the total number of biomarkers inside the blood vessels is a function of time.
Nevertheless, since the change in production rate of cancer biomarkers is very slow [22],
we assume a quasi-steady state behavior for the number of biomarkers in the blood vessels
during the comparatively short observation window.
• We calculate the time-dependent probability density function (PDF) of the location of
one biomarker released by a cancer cell inside a cancerous blood vessel. Subsequently, we
derive the steady-state spatial concentration of the biomarkers inside the cancerous blood
vessel, due to a continuous release of biomarkers. Using particle-based simulations, we
show that for blood vessels of small height, such as capillaries, arterioles, and venules, the
concentration of biomarkers inside the blood vessel is approximately uniform across the
cross-section.
• Based on the results obtained for one cancerous blood vessel, we extend our model
to networks comprising several blood vessels, which are part of the entire CS. To this
end, we decompose the networks into three main building blocks, namely straight edges,
junction nodes, and bifurcation nodes, and analytically characterize the impact of each block
on the steady-state concentration of the biomarkers in closed form. Since the numerical
evaluation of the expression for the biomarker concentration obtained from our analysis
may be challenging1, we also propose an approximation to obtain the concentration with
much less complexity. In Section VI, via particle-based simulations, we show that for
typical system parameter values for the blood fluid velocity and typical MNS and biomarker
diffusion coefficients, the results obtained based on the approximation are accurate.
• We also derive the statistics of the activation levels of the MNSs traveling through the
blood vessels of a given network. Furthermore, based on the proposed system model, we
formulate a hypothesis testing framework to decide at the FC whether cancer cells are
present in the CS or not. To this end, we derive the optimal Neyman-Pearson decision rule
[23] for a given number of MNSs observed and read out at the FC by assuming that the FC
1This is due to the fact that, for computation of the biomarker concentration, the inverse of a possibly ill-conditioned matrix
is needed.
5knows the structure of the entire network. We then derive a simple and practical detector,
which we refer to as sum detector, that adds up the activation levels of the MNSs observed
at the FC. Next, we evaluate the performance of the proposed detectors in terms of the
false alarm and missed detection probabilities via Monte Carlo simulations. For a sample
network consisting of several blood vessels, we show that while the LRT detector achieves
a higher performance than the sum detector at the expense of a higher complexity, both
detectors outperform a benchmark scheme with fixed nanosensors.
The remainder of this paper is organized as follows. In Section II, we provide the system
model. In Section III, we develop a model for cancerous blood vessels and derive the steady-
state distribution of the biomarkers inside the blood vessels of a sample network of the CS.
In Section IV, we derive the statistics of the activation levels of the MNSs that pass through
the network. The optimal and suboptimal detector design for the FC is presented in Section V.
Section VI provides extensive particle-based simulation results to verify all assumptions made
in the preceding sections as well as numerical results to assess the performance of the proposed
detectors. Finally, Section VII concludes the paper.
II. SYSTEM MODEL
In this section, we introduce the system model considered in this paper. We consider a part of
the CS comprising several blood vessels. The blood vessels may be interpreted as the edges of a
network. The edges may merge, thus forming nodes, cf. Fig. 1. We assume that in one specific
point of the network, proteins are released due to the presence of cancer cells. These proteins
serve as biomarkers for the cancer. Upon release, the biomarkers move through the network
driven by blood flow and diffusion. We inject Mmax MNSs at one specific site into the CS. Each
MNS can be potentially activated to a varying degree by biomarkers. In addition, we assume an
FC capable of reading the MNSs’ states when they reach the FC. Based on FC observations,
we construct a hypothesis testing framework and denote H0 and H1 as the hypotheses for the
normal (absence of cancer cells) and abnormal (presence of cancer cells) status, respectively.
Then, the aim is to reliably decide at the FC whether H0 or H1 is true based on the observations
read out from the MNSs.
In the following, we develop a simplified model for the CS suitable for formulating a decision
problem. Then, we provide a model for biomarker detection at the MNSs.
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Fig. 1. A schematic presentation of a sample 2-D network.
A. A Simplified Model for the Cardiovascular System
In general, the CS is highly complex. Therefore, in order to keep our analysis tractable, we
are interested in developing a simplified model, which retains the relevant characteristics of the
CS. To this end, we consider a similar model as the one proposed in [24, Ch. 20], where a
particle released into the CS can enter a limited number of main paths and move through them.
Furthermore, we assume that not only cancerous cells release biomarkers but also healthy cells
[25]. The biomarkers secreted by healthy cells can be interpreted as environmental noise. In
addition, instead of considering a complex 3-D model for the CS, to facilitate first-order insights
about the propagation of biomarkers and MNSs through the CS, we consider a simplified 2-D
model for the network, as depicted in Fig. 1. The low-dimensional model for the CS makes it
not only possible to gain general physical insight into the dynamics of the CS [26], but also
facilitates the derivation of closed-form expressions for the biomarker concentration and the
activation levels of the MNSs for the proposed MNS-based approach for the anomaly detection
problem.
B. Cancerous Blood Vessel
We adopt a simple model for the cancerous blood vessel. In particular, for the blood vessels, we
assume a 2-D rectangular shape with length d and height h and reflective boundaries. The cancer
biomarkers are released into one of the blood vessels at position (x, z) = (d0, 0), as depicted in
Fig. 1, and undergo advection in x-direction and independent diffusion in x- and z-directions.
We note that the blood in small vessels like capillaries can be modeled as a non-Newtonian
Casson fluid [27], which imposes a non-uniform flow velocity along the z-axis. However, for
7tractability of the analysis, and similar to [21], [28], and [29], we assume a uniform flow with
constant velocity v. Furthermore, we assume that the cancer resides in one specific capillary
while the released biomarkers spread into all neighboring edges and nodes. We also assume
that the biomarkers degrade at a rate of kDeg [s
−1] and are released at a constant rate of µ
[biomarkers·s−1] into the blood vessel [13], [25]. The release rate depends on the stage of the
cancer, i.e., in the early stages, it is very low, and in the final stages, it can be very high. For
the flow velocity change at the interconnections of the vessels, i.e., the nodes of the network,
we also assume uniform flow, where the velocity of the incoming and outgoing flows abruptly
changes [21], due to the conservation of mass. The mathematical model of the biomarker release
rate and the biomarker distribution inside the CS will be presented in Section III.
C. Mobile Nanosensors
MNSs are employed to decide on the presence of cancer cells in a network of interconnected
blood vessels. We assume that the MNSs are injected at one specific site of the network and
that each MNS has a small area, S, and can measure the number of biomarkers within this area
[13]. In addition, we assume that the MNSs are passive with respect to the biomarkers, i.e., the
MNSs and biomarkers move independently in the environment and do not interact with each
other. In particular, an MNS can be a natural or an engineered cell which can periodically and
locally measure and count the number of biomarkers inside its surface [4], [13], [30]–[34]. The
number of biomarkers inside an MNS can be determined either directly by counting the number
of biomarkers bound by suitable cell-surface receptors [33], or indirectly by measuring other
parameters, such as the pressure and temperature of the medium in the vicinity of an MNS’s
surface [34].
After MNS injection, based on the direction of the flow in the blood vessel network and
the topology of the network, the MNSs follow different routes where they may eventually
encounter the cancer biomarkers, e.g., when passing through cancerous tissue and capillaries.
The MNSs enter the cancerous vessel at positions (x, z) = (0, z0), where we model z0 as
random and uniformly distributed in [0, h]. As mentioned above, we assume that each MNS
can measure the number of biomarkers with a given periodicity. Similar to [35], we assume the
time interval between two consecutive measurements is large enough such that the observations
are independent. Furthermore, we assume that the MNS can accumulate successive observations
and the FC can read out the summation value. We will refer to this value as the activation
8level and denote it for the m-th MNS observed at the FC by random variable (RV) Am and
its realization by am, respectively. The probability mass function (PMF) of this RV will be
mathematically derived in Section IV.
D. Fusion Center
The MNSs can pass through different routes of the network and some may not arrive at the
FC. Since for a given MNS the selection of the path through the network is random, a released
MNS is observed at the FC with a certain probability ρ. Intuitively, ρ can be increased by
choosing a favorable location for the FC, increasing the observation window, or improving the
reception process at the FC. This can be achieved, for example, by employing magnetic MNSs,
which can be efficiently attracted to the FC by holding them in place by an external magnet,
see [36] and [37]. Here, we assume that the FC can observe and read the activation levels of all
MNSs that come in contact with it. After reading out the MNSs’ measurements, the FC makes
a decision regarding the presence of cancer cells. Optimal and suboptimal decision rules for the
FC will be provided in Section V.
III. BIOMARKER DISTRIBUTION
In this section, first we consider a single cancerous blood vessel and derive the distribution of
the biomarkers in it as a function of time and space. Then, we extend the obtained results to a
sample network of the CS and analyze the distribution of the biomarkers in the interconnected
blood vessels.
A. Biomarker Production Rate
In the literature, several models for the production rate of cancer cells inside a blood vessel
have been proposed [38]. However, most of these models do not include the production rate
of biomarkers secreted by cancerous and healthy cells. One recently established model for the
production rates of cancerous and healthy cells as well as the biomarkers secreted by these cells
is given in [25]. This model can be summarized as follows.
1) The total number of cancer cells inside the cancerous tissue, denoted by NC(t), follows a
Gompertzian function [38]
NC(t) = NC,0 exp
(
kGr
kDec
(1 − exp (−kDect))
)
, (1)
9where NC,0 is the initial number of cancer cells at time zero, and kGr and kDec are the
fractional growth and decay rates of the cancer cells, respectively. For kDect ≪ 1, i.e., in
the early stage of a cancer, (1) can be approximated by
NC(t) = NC,0 exp (kGrt) . (2)
2) Unlike the cancer cells, the number of healthy cells is assumed to be constant over time,
i.e., NH(t) = NH,0.
3) Cancerous cells and healthy cells secrete the same biomarkers into the medium with constant
shedding rates RC and RH, respectively, where RC ≫ RH. However, in the vasculature, on
average fractions of fH and fC of the biomarkers secreted by the healthy and cancerous
cells, respectively, will be present and the remaining fractions of biomarkers will be secreted
into tissue.
4) The biomarkers degrade uniformly in the blood vessel over time with constant degradation
rate kDeg.
Based on the above assumptions, the release rate of the biomarkers secreted by healthy cells is
constant and equal to fCRCNH,0. However, for the cancer cells, we obtain the rate of biomarker
release, denoted by µ [biomarkers·s−1], at time T as follows
µ(T) , fCRCNC,0 exp (kGrT) . (3)
For healthy cells, which cover the entire surface of the blood vessels, it can be shown that the
total number of secreted biomarkers that are present in the environment reaches a steady-state
value of fHRHNH,0/kDeg [25]. Moreover, at any location of the CS, we can model the number
of the biomarkers within a small area S by a Poisson PMF [39], [40], with a mean proportional
to S fHRHNH,0/kDeg. We denote this mean by Sξ, which does not depend on x nor z. On the
other hand, for cancer cells, the number of secreted biomarkers does not reach a steady state and
increases over time. Nevertheless, since the production rate kGr is very low (kGr < 10
−6 s−1 [22]),
using (2) we can model the number of cancer cells during a short time interval around T (e.g. a
few days), denoted by Tsteady, as constant. This implies a quasi-steady state where the secretion
rate is approximately constant and equal to µ(T) during time interval [T−Tsteady/2, T+Tsteady/2].
In the following subsections, we derive the spatial and temporal distribution of the biomarkers
under the quasi-steady state assumption with constant release rate (3).
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B. Local Cancerous Blood Vessel
In this subsection, we consider a single cancerous blood vessel and evaluate the distribution
of the biomarkers secreted by the cancer cells inside the blood vessel as a function of time and
space. This analysis is needed to determine the PMF of the activation level of an MNS that
enters the cancerous blood vessel.
In small blood vessels, the blood in the x-direction can be modeled as a non-Newtonian
Casson fluid, which imposes a non-uniform flow velocity profile along the z-axis [27], denoted
by v(z). Therefore, considering that the biomarkers are released by the cancer cells at position
(d0, 0) into the medium with a release rate of s(t; x, z) = µδ(x − d0)δ(z), where δ(·) is the delta
function, the following advection-diffusion equation describes the 2-D biomarker concentration
∂C(t; x, z)
∂t
= Db∇2C(t; x, z) − ∇ · (v(z)C(t; x, z)) − kDegC(t; x, z) + s(t; x, z), (4)
where ∇ · (·) is the divergence operator, ∇2 is the Laplace operator, and Db is the diffusion
coefficient of the biomarkers. Since v(z) is a function of z, usually numerical methods are used
to solve (4) [41]. However, as mentioned in Section II, in this paper, to gain first-order insight,
we consider a 2-D model with uniform flow, i.e., v(z) = v, which allows us to analytically solve
the differential equation in (4). In particular, for uniform flow, the advection-diffusion equation
for the concentration of the biomarkers inside the blood vessel simplifies to
∂C(t; x, z)
∂t
= Db∇2C(t; x, z) − v∇ · (C(t; x, z)) − kDegC(t; x, z) + s(t; x, z), (5)
with boundary condition
∂C(t; x, z)
∂z
= 0, for z = 0, h. (6)
To solve (5), we first derive the spatial PDF for impulsive release of one biomarker at time
t = 0, and then use it to determine the spatial distribution of the biomarkers when they are
released with constant rate µ. To this end, we consider one biomarker release at time t = 0,
i.e., s(t; x, z) = δ(t)δ(x − d0)δ(z) and denote the solution of (5) for this initial condition and
the boundary condition in (6) by p(t; x, z)u(t). This solution is the spatial PDF of the released
biomarker over time, where u(t) is the unit step function. Since for the considered model, the
biomarkers’ movements in the x- and z-directions are independent, we obtain [42]
p(t; x, z) = 1√
4piDbt
exp
(
−(x − d0 − vt)
2
4Dbt
)
︸                                   ︷︷                                   ︸
x-direction
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×
(
1
h
+
2
h
∞∑
k=1
exp
(
−Db
(
kpi
h
)2
t
)
cos
(
kpiz
h
))
︸                                                     ︷︷                                                     ︸
z-direction
exp
(−kDegt)︸          ︷︷          ︸
degradation
, (7)
where h is the height of the cancerous blood vessel. Then, the concentration of the biomarkers
in the blood vessel at time t and location (x, z) can be obtained as follows
C(t; x, z) =
∫ t
0
µp(t − τ; x, z)u(t − τ)dτ. (8)
Given (7), in the following lemma, by evaluating (8) we provide a closed-form expression for
the steady-state concentration of the biomarkers secreted by the cancer cells.
Lemma 1. For a single cancerous vessel with cancer cells located at (d0, 0) and biomarker
secretion rate µ, the steady-state concentration of cancer biomarkers at (x, z) is given by
C(x, z) =
∫ ∞
t=0
µp(t; x, z)dt
= µ
exp
(
(x−d0)v
2Db
(
1 − sgn(x − d0)
√
1 +
4DbkDeg
v2
))
hv
√
1 +
4DbkDeg
v2
+ 2µ
∞∑
k=1
cos kpiz
h
exp
(
(x−d0)v
2Db
(
1 − sgn(x − d0)
√
1 +
4DbkDeg
v2
+
4k2pi2D2
b
h2v2
))
hv
√
1 +
4DbkDeg
v2
+
4k2pi2Db
h2v2
, (9)
where sgn(x) is the sign function which is 1 for x > 0, 0 for x = 0, and −1 for x < 0.
Proof: C(x, z) is obtained by substituting (7) into (8) and taking the limit t →∞, where µ
is given by (3).
Remark 1. It can be shown that for small blood vessels (such as capillaries, arterioles, and
venules, where h < 100 µm [43]), the steady-state concentration of the biomarkers secreted by
cancer cells C(x, z) is approximately constant with respect to z for a given x , d0. Therefore,
we can approximate the concentration as
C(x, z) = C(x)
h
, 0 ≤ z ≤ h, (10)
where
C(x) =
∫ h
z=0
C(x, z)dz = µ
exp
(
(x−d0)v
2Db
(
1 − sgn(x − d0)
√
1 +
4DbkDeg
v2
))
hv
√
1 +
4DbkDeg
v2
. (11)
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This approximation is further investigated in Section VI. We use this result to solve a 1-D
advection-diffusion equation in Section III-C for a network of connected blood vessels.
Remark 2. For typical system parameters for blood vessels and biomarkers, we have 4DbkDeg/v2
≪ 1. Hence, (11) can be simplified as
C(x) ≈

µ
v exp
( (x−d0)v
Db
)
if x ≤ d0,
µ
v exp
(−(x−d0)kDg
v
)
if x ≥ d0.
(12)
C. Network of Blood Vessels
In this subsection, we derive closed-form expressions for the distribution of the concentration
of the biomarkers inside a given network of blood vessels. The secreted biomarkers spread
across multiple blood vessels which imposes further boundary conditions on the advection-
diffusion equation in (5). Therefore, we cannot directly apply the results derived in (9) for one
vessel to a network of several connected vessels. Since the dependence of the concentration of
the biomarkers on z is negligible when h is not very large, see Remark 1, we approximated
the distribution of the biomarker concentration along the z-axis as uniform (10). Therefore, in
this subsection, we consider a 1-D blood vessel network model and analyze how junction and
bifurcation nodes influence the distribution of the biomarkers in the connected blood vessels.
Then, considering the uniform distribution of the biomarkers with respect to z, we can obtain
the 2-D concentration of the biomarkers based on the 1-D concentration.
As can be observed from Fig. 1, a network typically comprises three fundamental blocks:
I: Straight edges: The blood vessels that connect two adjacent nodes.
II: Junction nodes: In a junction node, two or more incoming blood flows join to become one
single flow.
III: Bifurcation nodes: In a bifurcation node, an incoming blood flow is split into two or more
outgoing flows.
In Section III-B, we provided the steady-state concentration of the biomarkers for a local
straight edge in (10). In the following, we study the effect of junction and bifurcation nodes on
the concentration of the biomarkers inside the edges.
1) Junction Node: For a junction node, we consider the case where Q small edges are joined
to form a bigger edge, see Fig. 2a). We assume that the j-th incoming edge has flow velocity v j
and cross-sectional area S j , and the outgoing edge has flow velocity vO and cross-sectional area
SO. Then, based on the first law of dynamic flow, the incoming and outgoing flow rates must
13
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Fig. 2. a) Schematic model of a junction node, b) schematic model of a bifurcation node.
be identical, which results in vO =
∑Q
j=1
Sjv j
SO
[44]. Without loss of generality, we assume that the
first edge with velocity v1 secretes cancer biomarkers at location x = d0 into the medium, and is
joined with the Q−1 other edges at x = d0 + L to yield a larger edge with flow velocity vO. We
are particularly interested in finding the concentration of biomarkers inside the first small edge
and the outgoing edge. Since we have assumed steady-state conditions, the following differential
equation describes the 1-D concentration of the biomarkers inside the first small edge and the
outgoing edge
Db
∂2C(x)
∂x2
− vg ∂C(x)
∂x
− kDegC(x) = 0, g = 1,O, (13)
where steady-state operation was assumed, i.e., ∂C(x)/∂t = 0. Since Db, v, and kDeg are all
positive, the solution of (13) will be a combination of exponential functions of the form exp(λx)
where the coefficients λ must be roots of following algebraic equation [45]
Dbλ
2 − vgλ − kDeg = 0, g = 1,O, (14)
which has two possible solutions. Furthermore, based on the fundamental laws of diffusion and
conservation of mass, the following two conditions have to be satisfied: i) the concentration of
the molecules must be continuous, ii) the flux must be continuous and can be obtained as [46]
J(x) = −Db ∂C(x)
∂x
+ vgC(x), g = 1,O. (15)
In the following, we analytically derive the concentration of the biomarkers and provide a suitable
approximation for simpler evaluation.
Exact Solution: Based on the above discussion, the steady-state concentration of the biomark-
ers can be shown to have the following general form [45]
C(x) =

B1 exp
(
λ+,1(x − d0)
)
if x ≤ d0,
B2 exp
(
λ+,1(x − d0)
)
+ B3 exp
(
λ−,1(x − d0)
)
if d0 ≤ x ≤ d0 + L,
B4 exp
(
λ−,O (x − d0 − L)
)
if x ≥ L + d0,
(16)
14
where
λ±,1 =
v1
(
1 ±
√
1 +
4DbkDeg
v2
1
)
2Db
, λ−,O =
vO
(
1 −
√
1 +
4DbkDeg
v2
O
)
2Db
. (17)
Here, B1, B2, B3, and B4 are unknown parameters that have to be determined. Combining (13)–
(17), we arrive at the linear equation M®x = ®y with
M=

1 −1 −1 0
Dbλ+,1 −Dbλ+,1 −Dbλ−,1 0
0 −exp (λ+,1L) −exp (λ−,1L) 1
0 −Dbλ+,1exp
(
λ+,1L
) −Dbλ−,1exp (λ−,1L) v1 − vO + Dbλ−,O

, ®x=

B1
B2
B3
B4

, ®y=

0
µ
0
0

.
(18)
The unique solution for ®x can be obtained as ®x = M−1®y, where M−1 is the inverse of matrix M.
Approximate Solution: Due to the possibly large values for λ±,1 and λ−,O, matrix M may
be ill-conditioned, which makes the determination of unknown parameter vector ®x numerically
challenging. Hence, in the following, we propose a simple approximate solution to (13). In
particular, we consider the following approximations:
I: Suppose that the flow in edge 1 with velocity v1 is not influenced by the other connected
blood vessels at x = d0 + L. Then, we use the solution for a local straight edge in (11) for
x ≤ d0 + L.
II: Consider the concentration at x = d0 + L as a virtual source for the blood vessel with
outgoing flow with velocity vO. Then, we employ (11) for x ≥ d0 + L and flow velocity
vO.
Considering these approximations, the approximated solution can be obtained as follows
C(x) =

µ
exp
(
(x−d0)v1
2Db
(
1−sgn(x−d0)
√
1+
4DbkDeg
v2
1
))
v1
√
1+
4DbkDeg
v2
1
if x ≤ d0 + L,
(
µ exp
(
Lv1
2Db
(
1 −
√
1 +
4DbkDeg
v2
1
)))
×
exp
(
(x−d0−L)vO
2Db
(
1−
√
1+
4DbkDeg
v2
O
))
vO
√
1+
4DbkDeg
v2
O
if x ≥ d0 + L.
(19)
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Remark 3. Similar to Remark 2, for typical parameter values for biomarkers and blood vessels,
we can assume that 4DbkDeg/v21 ≪ 1 and 4DbkDeg/v2O ≪ 1. Hence, (19) can be simplified as
C(x) ≈

µ
v1
exp
( (x−d0)v1
Db
)
if x ≤ d0,
µ
v1
exp
(−(x−d0)kDeg
v1
)
if d0 ≤ x ≤ d0 + L,
µ
vO
exp
(
−kDeg × (vO−v1)L+(x−d0)v1v1vO
)
if x ≥ d0 + L.
(20)
2) Bifurcation Node: For a bifurcation node, we assume that one edge is divided into Q edges.
Furthermore, let us assume that the incoming flow velocity is v0 and the outgoing flow velocity
for the j-th edge ( j = 1, . . . ,Q) is v j , see Fig. 2b). The derivation of an expression for the
velocity of the outgoing flows involves both the first and second law of fluid mechanics, which,
in turn, requires knowledge of the entire network topology [44]. Therefore, similar to Section
III-C1, we assume that the flow velocities of the edges are given. Then, using the principle of
mass conservation [44], we can derive the probability that a biomarker secreted at x = d0 in the
incoming edge, enters the j-th outgoing edge at x = d0 + L as follows
p j =
S jv j∑Q
j=1
S jv j
, j ∈ {1, · · · ,Q}, (21)
where S j is the cross-sectional area of the j-th outgoing edge. By using a similar approach as
in Section III-C1, we arrive at the following analytical expression for the concentration of the
biomarkers at the bifurcation node
C(x) =

C1 exp
(
λ+,0(x − d0)
)
if x ≤ d0,
C2 exp
(
λ+,0(x − d0)
)
+ C3 exp
(
λ−,0(x − d0)
)
if d0 ≤ x ≤ d0 + L,
p jC4 exp
(
λ−, j (x − d0 − L)
)
if x ≥ d0 + L, ∀ j ∈ {1, · · · ,Q},
(22)
where λ+,0 and λ−,0 are the positive and negative roots of Dbλ2−v0λ−kDeg = 0, respectively, and
λ−, j is the negative root of Dbλ2 − v jλ − kDeg = 0. Similar to the approach proposed in Section
III-C1, by considering the initial value and boundary conditions at x = d0 and x = d0 + L, we
can construct a linear system of equations to determine C1,C2,C3, and C4 as well as the exact
and approximate solutions for C(x) in (22), which we omit here due to space limitation.
Based on the results obtained in this section, for any given network, inside each blood vessel
of the network, we can derive the concentrations of the biomarkers, C(x, z), secreted by cancer
cells. That is, by plugging the 1-D expressions into (10) we obtain the 2-D concentration of the
biomarkers.
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D. PMF of the Number of Biomarkers
In the following, we derive the spatial PMF of the number of biomarkers inside a small virtual
observation area S representing one MNS. In the next section, we use this PMF to derive the
activation level of the MNSs. With C(x) derived in Sections III-B and III-C and assuming that S
is small so that the concentration of biomarkers is approximately uniform inside the observation
area, the mean number of biomarkers inside the area S centered at position (x, z) is given by
SC(x)/h. However, this does not directly give insight about the PMF of the random number of
biomarkers inside the observation area. In the following, we show that the number of biomarkers
inside this area generally follows a Poisson Binomial distribution.
Let us denote the PMF for having at time t, n biomarkers out of the N = µt biomarkers
released in total, which undergo advection and diffusion and may degrade until time t, inside
the observation area centered at (x, z) by pbio,n(t; x, z). To derive pbio,n(t; x, z), suppose that the
release time for the n-th biomarker, n ∈ {1, . . . , N}, is Tn. Hence, the probability of having
the n-th biomarker inside the observation area at time t is given by Sp(t − Tn; x, z)u(t − Tn),
where p(·; ·, ·) is given in (7). Since the biomarkers have different release times, the number
of biomarkers inside the observation area at time t is a Bernoulli trial with different success
probabilities for different biomarkers, which leads to a Poisson Binomial distribution. Hence,
the probability of simultaneously having n of the released biomarkers inside the observation area
can be expressed as
pbio,n(t; x, z) =
∑
B∈Fn
∏
i∈B
Sp(t − Ti; x, z)
∏
i∈Bc
(1 − Sp(t − Ti; x, z)) , (23)
where Fn is the set of all subsets of n integers {1, 2, 3, ...,N}, with
Fn = (Nn ) , where  ·  denotes
the cardinality of a set .
The Poisson Binomial distribution is cumbersome to work with, but can often be approximated
by a Poisson distribution when the number of trials is high and the success probability is small,
cf. [47]. To this end and for simplicity, we approximate (23) by a Poisson PMF with mean
SC(x)/h. For our system model, this approximation is accurate when the number of released
biomarkers is high; and for each biomarker, the probability of being observed inside the MNS is
small. In Section VI, we validate the accuracy of this approximation via particle-based simulation.
Therefore, we model the PMF for the number of biomarkers, secreted by cancerous and healthy
cells, found inside a small observation area S centered at (x, z), as
Nbio(x) ∼ Poisson
(
S
C(x)
h
+ Sξ
)
, (24)
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where Poisson(γ) denotes a Poisson distribution with mean γ. Here, we have denoted the number
of biomarkers, secreted by healthy cells, inside the observation area by a Poisson RV with mean
Sξ.
IV. MNS ACTIVATION LEVEL STATISTIC
In the previous section, we derived the concentration of the biomarkers inside a network of
blood vessels. Using this result, we then derived the PMF of the number of biomarkers inside
a small area in the network. In this section, we use the results of Section III, to determine the
PMF of the activation levels of the MNSs, which is needed for detection at the FC.
To derive the PMF of the activation level of the MNSs, we have to consider all possible
routes inside the network between the injection site and the FC as well as the distribution of
the biomarkers inside each edge of the network. To formulate this rigorously, we assume that
the network between the injection site and the FC contains L different edges, where the l-th
edge, l ∈ {1, . . . , L}, is denoted by El. Then, based on the topology of the network and the flow
directions inside the vessels, we assume that there exist R different routes starting at the injection
site and ending at the FC. We denote the set that contains the indices of the edges that construct
the r-th route, r ∈ {1, . . . , R}, by Rr . In general, which route an MNS moves through is not a
priori known and is modelled as an RV. Therefore, for the m-th observed MNS at the FC, we
model the route that it has taken by RV Gm, where Gm ∈ {1, 2, . . . , R}. We denote the probability
P(Gm = r) that the m-th MNS passes through the r-th route by qr . We also define C{l}(x) as the
concentration of the biomarkers at local position x inside the l-th edge, which depending on the
topology of the network, can be obtained from (11), (19), or (22). Furthermore, based on the
fact that each MNS takes measurements periodically and the lengths of the routes, in general,
are not the same, the measurement time inside each edge depends on the route r that the MNS
travels along. We denote the set of time instances at which an MNS traveling via the r-th route
takes measurements inside the l-th edge by T {l}r . We note that since the l-th edge may not be
included in Rr , set T {l}r can be empty. Furthermore, we denote the number of biomarkers that
the m-th MNS observes inside the l-th edge at time t by RV N
{l}
m (t), which has a Poisson PMF,
cf. (24). Now, based on the definition of the activation level am given in Section II-C, we can
express the PMF for the activation level of the m-th MNS as
P(Am = am) =
R∑
r=1
P (Gm = r)P
(
Am = am
r )
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=
R∑
r=1
P (Gm = r)P
©­­«
∑
l∈Rr
∑
t∈T {l}r
N
{l}
m (t) = am
ª®®¬
=
R∑
r=1
qrP
©­­«
∑
l∈Rr
∑
t∈T {l}r
N
{l}
m (t) = am
ª®®¬ . (25)
To evaluate (25), first we need to determine the PMF of N
{l}
m (t). However, since the position of the
MNS in x-direction is generally not deterministic due to diffusion, to derive the PMF of N
{l}
m (t),
we employ a simplification. In particular, due to the small value of the diffusion coefficient,
Dn, of typical MNSs [25], advection is dominant over diffusion regarding the movement of the
MNSs along the x-axis. For instance, for capillaries, normally v ≥ 0.03 cm·s−1, d ≈ 9×10−2 cm,
and Dn ≤ 10−8 cm2·s−1 holds [13], [25], [48]. In this case, the distance that an MNS can travel
by advection during a test time interval of Ttest , d/v = 0.09/0.03 = 3 s, is d = 9 × 10−2 cm
which is much larger than the standard deviation of the distance that the MNS typically moves
by diffusion during the same time interval,
√
2DnTtest = 2.4 × 10−4 cm2. Hence, the locations
where measurement are taken along the x-axis are practically deterministic. Thus, we define the
set of deterministic measurement positions for an MNS during its journey inside the l-th edge
via the r-th route by X{l}r =
{
x
x = vl t,∀t ∈ T {l}r }, where vl is the flow velocity in the l-th
edge. Therefore, since an MNS’s measurements are assumed independent, based on the thinning
property of Poisson processes, we obtain the activation level conditioned on the MNS having
taken the r-th route as
Am
r = ∑
l∈Rr
∑
t∈T {l}r
N
{l}
m (t) ∼ Poisson
©­­­­«
∑
l∈Rr
∑
x∈X {l}r
©­­­­«
S
C{l}(x)
h︸    ︷︷    ︸
Cancerous cells
+ Sξ︸︷︷︸
Healthy cells
ª®®®®¬
ª®®®®¬
. (26)
Note that in (26) the contributions of both cancerous and healthy cells are included. For ease
of presentation, we define ζr and ϑr as the mean values of the conditional RV Am
r under
hypotheses H0 and H1, respectively, which can be written as
ζr , Sξ
∑
l∈Rr
X{l}r 
ϑr ,
∑
l∈Rr
∑
x∈X {l}r
(
S
C{l}(x)
h
+ Sξ
)
.
(27)
2We note that since for biomarkers, normally Db ≥ 10−6cm2s−1 [13], [25], the standard deviation of the distance that a
biomarker moves by diffusion during Ttest is larger than 2.4 × 10−3 cm and not negligible compared to the distance that the
biomarker moves by advection.
19
Therefore, the activation level given in (25) can be represented for hypotheses H0 and H1 as
follows
P(Am = am) =

∑R
r=1 qr
exp(−ζr )(ζr )am
am!
, under H0,∑R
r=1 qr
exp(−ϑr )(ϑr )am
am!
, under H1.
(28)
V. DETECTOR DESIGN AT FC
Based on the results derived in Section IV, in this section, we derive the optimal decision
rule at the FC with respect to the Neyman-Pearson criterion [23], which is referred to as the
likelihood ratio test (LRT) and relies on the knowledge of the network topology between the
injection site and the FC. However, in practice, we do not know the biomarker secretion rate
and the location of the cancer cell. Therefore, we also propose a simple suboptimal detector that
does not require knowledge of the network topology. The optimal LRT decision rule serves as
an upper bound for the performance of any suboptimal detector for the proposed MNS-based
system. We note that the number of MNSs observed at the FC follows a Binomial distribution
with Mmax trials and success probability ρ, Bi(Mmax, ρ), cf. Section II-D. Here, we assume that
the FC makes a decision after observing M MNSs out of all Mmax injected MNSs.
Let ®AM denote an RV vector modeling the vector containing the activation levels of all M
MNSs observed during the observation window, i.e., ®AM = [A1, . . . , AM]T , and let ®aM be a
realization of ®AM . According to the Neyman-Pearson criterion, the goal is to design the optimal
detector that minimizes the missed detection probability subject to a pre-assigned upper bound
α on the false alarm probability, i.e.,
min
decision rules
Pm, subject to Pfa ≤ α, (29)
where Pfa and Pm are the false alarm and missed detection probabilities, respectively. The solution
to (29) is the well-known LRT [23] that compares the log-likelihood ratio (LLR) with a threshold
denoted by τ, where τ is chosen such that Pfa = α. In particular, the decision rule for the LRT
can be characterized as
doptimal =

0, if LLR(®aM) 6 τ,
1, otherwise,
(30)
where doptimal = j means that the detector selects hypothesis Hj, j = 0, 1. In (30), LLR(®aM) is
given by
LLR(®aM) = log
©­­«
P
(
®AM = ®aM |H1
)
P
(
®AM = ®aM |H0
) ª®®¬ . (31)
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In the following, we derive LLR(®aM) for the problem at hand. Since the movements of different
MNSs are independent, the activation levels of different MNSs are statistically independent,
which results in
P
(
®AM = ®aM |Hj
)
=
M∏
m=1
P
(
Am = am |Hj
)
, j = 0, 1. (32)
Therefore, based on (31) and (32), we can express LLR as
LLR(®aM ) =
M∑
m=1
log
(
P (Am = am |H1)
P (Am = am |H0)
)
,
M∑
m=1
LLR(am), (33)
where using (28) we obtain
LLR(am) = log
(∑R
r=1 qr exp (−ϑr )ϑamr∑R
r=1 qr exp (−ζr) ζ amr
)
(34)
for the LLR of the observation of the m-th MNS.
Since in reality the network topology, and hence the values of ϑr and ζr are not known at the
FC, we propose a simple alternative but suboptimal detector that does not need knowledge of
the network topology. The decision rule of this detector, which we refer to as sum detector, is
as follows
dsum detector =

0, if
∑M
m=1 am 6 τ
′,
1, otherwise,
(35)
where τ′ is chosen such that the decision rule in (35) yields Pfa = α. In Section VI-B, we
evaluate the performance of the proposed detectors in terms of Pfa and Pm.
VI. SIMULATION RESULTS
In this section, we first validate the system model and the assumptions made for the analysis
presented in this paper via particle-based simulation. Then, we provide Monte Carlo simulation
results to assess the performance of the proposed detection schemes.
A. Model and Assumption Verification
We first consider a single blood vessel which is sufficient to verify most of our assumptions.
Subsequently, we introduce an example network for a more thorough analysis.
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TABLE I
LIST OF DEFAULT SIMULATION PARAMETERS [25].
Parameter Value Parameter Value
Db 10
−6cm2s−1 Dn 10−8cm2s−1
kDeg 2 × 10−4s−1 v 3 × 10−2cm s−1
kGr 4.63 × 10−7s−1 {µ, ξ} {1 s−1, 104 cm−2}
kDec 1.49 × 10−11s−1 NC,0 1
fCRC 10
−1 h 4 × 10−3 cm
S 10−5 cm2 d0 0 cm
1) Single Blood Vessel: To verify our analysis, we perform a 2-D particle-based simulation of
both the MNSs and the biomarkers secreted by the cancer cells. Table I summarizes the system
parameters that are used for all simulations, unless stated otherwise. Simulation results are
averaged over 103 independent realizations of the biomarker release, where for each realization,
we assume that the biomarkers are released into the blood vessel with rate µ = 1 s−1. This rate
is calculated via (3) for T ≈ 2 months, i.e., the early stage of a cancer.
Figs. 3a) and b) depict the average total number of biomarkers inside the blood vessel over
time, along with their distribution with respect to x, where the biomarkers are released into the
medium at time t = 0 and position x = d0 = 0. From Fig. 3a) we observe that about 8 hours (i.e.,
28800 s) after the start of secretion, the total number of biomarkers inside the medium reaches
its asymptotic value, which means that the integral in (9) has reached its asymptotic value
for t > 8 hours. Furthermore, from Fig. 3b) we observe that the biomarkers are exponentially
distributed along the x-axis for x > 0, which indicates that the concentration of the biomarkers
decreases rapidly as the distance from the release point increases. This motivates cancer detection
via MNS as proposed in this paper. Moreover, the concentration of the biomarkers at the left
hand side of the release point is approximately zero, which is consistent with the approximation
in (12). The results obtained with the exact (analytical) and approximate expressions derived
for straight blood vessels in (11) and (12), respectively, are in excellent agreement with the
simulation results.
Fig. 4 shows the histograms for the numbers of biomarkers inside rectangles of area S =
(4 cm) × (2 × 10−4 cm) = 8 × 10−4 cm2 centered at four different sample positions inside the
blood vessel, along with their Poisson PMF approximations according to (24). As can be seen,
the histogram for the number of biomarkers inside the rectangles is well approximated by a
Poisson PMF for all considered cases. This analysis confirms the accuracy of approximating the
number of the biomarkers inside a small area by a Poisson PMF. Finally, by comparing Figs. 4a)
and 4b) as well as Figs. 4c) and 4d), we observe that the PMF for the number of biomarkers is
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Fig. 3. a): Average total number of biomarkers present inside the blood vessel. b): Distribution of the mean number of biomarkers
versus x. The analysis and approximation results are obtained using (11) and (12), respectively.
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Fig. 4. Poisson PMF approximation (24) and histogram derived from particle-based simulation for the numbers of biomarkers
inside rectangles of area S = 8 × 10−4 cm2 centered at four different positions inside the blood vessel.
practically independent of z, which validates the assumptions made in Section III, i.e., a uniform
distribution of the biomarkers in z-direction for small blood vessels.
To investigate the effect of the blood vessel height on the distribution of the biomarkers, in
Figs. 5a), b), c), and d), we plot the biomarker concentration versus z for different values of x
and h. As can be observed, the distribution of the mean number of biomarkers inside the blood
vessel in the vicinity of the secretion point (x = 0) is not uniform in z. However, already for
x = 5 µm, for relatively small blood vessels (h ≤ 100 µm), the distribution of the biomarkers
with respect to z becomes uniform. On the other hand, for large blood vessels, this uniformity
does not hold. As Figs. 5c) and 5d) show, for the considered values of x and blood vessel heights
of 200 µm and 300 µm, the distribution of the biomarkers is not uniform over z, but is higher
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Fig. 5. Impact of blood vessel height on the concentration of the biomarkers (9) over z.
for smaller z, as the biomarker secretion point is located at z = 0. Hence, based on the results
obtained in Fig. 5, we can conclude that the assumption of approximately uniform concentration
for x , d is not only valid for capillaries (h < 10 µm), but for larger blood vessels such as
arterioles and venules, with heights smaller than 100 µm.
Fig. 6 depicts the trajectories of four independent MNSs entering a blood vessel of length
d = 1000 µm at random z positions. In this figure, we investigate the effect of MNS diffusion on
the mean value of the activation levels of the MNSs during their passage of the blood vessel. We
adopt time intervals of length 0.01d/v between consecutive measurements such that each MNS
takes approximately 100 measurements. As can be observed, although each MNS diffuses in z-
direction, the mean values of the activation levels of the MNSs, given in the legend of Fig. 6, are
relatively close to each other, which is in agreement with the assumption of uniform biomarker
distribution over z. Moreover, since the number of measurements made by each MNS is 100 and
is equal to the number of measurements that we expected by advection, the effect of diffusion
in x-direction is negligible in comparison to advection, which justifies the assumption made in
Section IV for derivation of (26). This is expected since the MNSs’ movement by advection, i.e.,
d = 10−1 cm, is two orders of magnitude larger than the typical movement caused by diffusion
during the time that the MNS is inside the vessel, i.e.,
√
2Dnd/v = 2.5 × 10−4 cm.
2) Network of Blood Vessels: In the following, we study the methods proposed in Section III-C
for evaluating the biomarker concentration in a network of blood vessels. In Fig. 7, we show
a sample network of blood vessels which is a simplified version of the network given in Fig.
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Fig. 6. Trajectories of four different MNSs for µ =
105 s−1, h = 10 µm, and d = 1mm. In the legend, the
mean value of the MNSs’ activation levels (27) is given.
FC
site
Injection
Fig. 7. A sample network containing 16 edges and 5
nodes.
1, where all blood vessels have identical cross-section areas. This network contains five nodes,
L = 16 edges, and R = 4 possible routes between the injection site and the FC. For this
network, the probability that a released MNS is observed at the FC is ρ = 0.125. The MNSs
are released at the injection site in edge E1 to be finally observed at the FC located in edge
E14. In general, the lengths of the blood vessels in the human body ranges from less than
1 cm to 100 cm [48]. Hence, the distance between the injection site and the FC could be
from tens of centimeters to a few meters. In addition, the number of blood vessels inside the
network between an injection point and an FC could be on the order of thousands. However,
to gain insight into the impact of the different parameters for system design, in Fig. 7, we
assume there are only 16 relevant (straight) edges with relatively large values for their lengths,
i.e., 96 cm for all vessels. We note that the order of the adopted lengths is in line with the
values previously used in the MC literature to model blood vessels for drug delivery, cf. [49].
We also assume equal heights of h = 80 µm for all edges. The biomarkers are released at
edge E2, at a distance of d0 = 10 cm from node N1, as depicted in Fig. 7. In addition, we
consider typical flow velocities for all edges. In particular, we assume that the flow velocity
in edge E1 is v1 = 0.04 cm·s−1. Then, since all edges have the same cross-section area and
using (21), the flow velocities in the other edges are obtained as v2 = v3 = 0.02 cm·s−1,
v4 = v5 = v6 = v7 = v8 = v9 = v10 = v12 = v13 = v14 = v15 = v16 = 0.005 cm·s−1, and
v11 = 0.01 cm·s−1. Furthermore, in the particle-based simulation, we assume that the velocity
changes abruptly at the nodes. Finally, because of the symmetry of the considered network, at
each bifurcation node (N1, N2, and N5), the released biomarkers and MNSs enter the outgoing
flows with equal probability. For example, each particle that moves through edge E2 and arrives
at node N2, enters each of the edges E4, E5, E6, and E10 with probability 0.25.
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Fig. 8. Concentration of biomarkers, C{l }(x), in different edges of the network in Fig. 7.
In Fig. 8, the concentration of the biomarkers, secreted by cancer cells, inside the sample
network, C{l}(x), is plotted versus the local x-axis of the edges, where we have averaged
over 2 × 103 independent realizations of the particle-based simulations. We have plotted the
concentrations of the biomarkers in edges E2, E6, E10, E11, and E14, which are the only edges
that contain biomarkers and are included in at least one route between the injection site and the
FC. In addition, we also show results for the approximate solution for the concentration of the
biomarkers (20). We note that, for the network considered in Fig. 7, the exact solution for the
concentration of the biomarkers (18), (22) yields practically identical results to the approximate
solution. Hence, for clarity, we only show the results for the approximate solution in Fig. 8.
As can be observed from Fig. 8, the simulated mean number of the biomarkers is in excellent
agreement with the approximate result. In addition, we observe that at junction nodes at which
the velocity of the outgoing flow is higher than that of the incoming flow, for instance at node
N3, two phenomena occur. First, at node N3, the concentration at the beginning of the outgoing
edge E11 is lower than that at the end of edge E6. Second, the rate of exponential decrease of the
concentration of the biomarkers inside the outgoing edge decreases. That is, inside edge E6, the
concentration of the biomarkers quickly decreases, while inside edge E11, it slowly decreases.
Both of these observations are consistent with the expressions provided in (12), (20), and (22),
where the concentration is proportional to (1/v)exp (−kDegx/v) .
B. Performance Evaluation
In the following, we evaluate the performances of the proposed LRT and sum detectors and
compare them with a benchmark scheme where the nanosensors are not mobile and are fixed
at the FC. In particular, the benchmark scheme, which is similar to a conventional blood test,
measures the biomarker concentration at a fixed location, and then employs equal gain combining
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(EGC) for the observations gathered by different sensors. Since the activation levels of fixed
nanosensors are Poisson distributed, EGC is the optimal combining rule [23]. Furthermore,
we assume a large enough time interval of 800 s between consecutive measurements of the
MNSs to have independent measurements on each edge, cf. [35]. Hence, the number of mea-
surements taken on the edges having flow velocities of 0.04 cm·s−1, 0.02 cm·s−1, 0.01 cm·s−1,
and 0.005 cm·s−1 is 3, 6, 12, and 24, respectively. Besides, to have a fair comparison between
the proposed scheme and the benchmark scheme, we employ the same number of sensors in
both cases. That is, although the number of MNSs observed at the FC follows the Binomial
distribution Bi(Mmax, ρ), since Mmax MNSs are released at the injection site, we employ Mmax
nanosensors for the benchmark scheme. In addition, we use the same average number of mea-
surements for the MNSs and the fixed nanosensors for the proposed MNS-based approach and the
benchmark scheme, respectively. Furthermore, MNSs moving through different routes between
the injection site and the FC have different activation level means. Applying the concentrations
of the biomarkers secreted by cancer cells shown in Fig. 8 in the inner summation in (26), i.e.,
ml ,
∑
x∈X {l}r SC
{l}(x)/h, we obtain the mean values for the activation levels of the MNSs passing
through the different edges as m2 = 1.28, m6 = m10 = 0.75, m11 = 0.006, and m14 = 0.003.
We note that for the considered network topology, ml does not depend on the route that the
MNSs take. Also, the mean value of the number of biomarkers secreted by the cancer cells
and observed at the FC for each measurement for the benchmark scheme is 10−5. Finally, as
we are interested in the early stages of a cancer, we assume the presence of a relatively large
environmental noise, which reflects the impact of healthy cells. To this end, a Poisson distributed
RV with mean Sξ = 0.1 is employed to model the impact of the environmental noise.
In Fig. 9, we compare the performance of the proposed MNS-based approach with that of the
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benchmark scheme. In particular, in this figure, we plot the probability of missed detection versus
the biomarker secretion rate for a given probability of false alarm of Pfa = α = 10
−2, Mmax = 100,
and ρ = 0.125 by employing Monte Carlo simulation for 4 × 105 independent realizations. For
each secretion rate µ, we have chosen appropriate thresholds for all considered detection schemes
such that Pfa = 10
−2, and based on these thresholds we have evaluated Pm. In our simulation,
for each of the possible routes R1 = {1, 2, 10, 14},R2 = {1, 2, 6, 11, 14},R3 = {1, 3, 12, 14}, and
R4 = {1, 3, 7, 11, 14}, we have evaluated the probability that a released MNS passes through
that route (qr = 1/32, r = 1, 2, 3, 4) as well as the mean number of biomarkers observed by
each MNS (ϑr and ζr). Based on this, we have constructed the LRT and sum detectors for
the MNS scheme derived in (30) and (35), respectively. For the benchmark scheme, we have
employed EGC. As expected, the LRT detector outperforms the sum detector at the expense
of a substantially higher complexity. In addition, we can observe that to achieve a probability
of missed detection of Pm = 10
−3 with the proposed MNS-based scheme employing the sum
detector, the biomarker release rate has to be around 3 s−1. The benchmark scheme requires
release rates larger than 3400 s−1 to achieve the same performance. Fig. 9 shows that during the
time interval in which µ changes from 0.5 s−1 to 2000 s−1, or equivalently a time interval of
7 months, cf. (3), the benchmark scheme cannot even achieve a probability of missed detection
of Pm = 10
−1. For the set of parameters considered here and the considered example network,
Fig. 9 shows that the proposed simple sum detector for the MNS-based approach can detect the
presence of cancer at least 6 months earlier than the benchmark scheme. Although the actual
CS is much more complex than the sample network in Fig. 7, we expect that using the proposed
MNS-based approach significantly improves the probability of detecting cancer compared to the
blood sample tests which are widely used now and are similar to our benchmark scheme.
Finally, in Fig. 10, we investigate the impact of the number of the MNSs observed at the FC
on the performance of the proposed sum detector. We show the probability of missed detection
versus the probability of false alarm based on Monte Carlo simulation of 4×105 realizations. The
number of used MNSs is an important design parameter for early cancer detection. As can be
observed, as the number of MNSs increases, the performance of the proposed detector improves
significantly.
VII. CONCLUSIONS
In this paper, we studied anomaly detection inside blood vessels where multiple MNSs are
injected and pass through the blood vessels. The MNSs sense the presence of an anomaly by
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detecting the biomarkers secreted by cancer cells. The final decision regarding the presence
of anomaly is made at an FC based on the activation levels of the observed MNSs. For this
collaborative anomaly detection scheme, we first considered a single cancerous blood vessel and
derived the spatial distribution of the biomarkers in it as a function of time. Then, we extended the
obtained results to a sample network of the CS and analyzed the distribution of the biomarkers in
the connected blood vessels of the network. Based on the biomarker distribution, we modelled the
statistics of the activation levels of the MNSs observed at the FC. We also verified the accuracy of
the models proposed in this paper via particle-based simulations. Finally, we derived the optimal
decision rule as well as a simple sum detector for the FC and compared their performances via
simulation to that of a benchmark scheme. Our simulations revealed that while the optimal LRT
detector achieves a higher performance than the sum detector at the expense of a substantially
higher complexity, both proposed detectors are superior to the benchmark scheme.
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